Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04277546 · ClinicalTrials.gov registry record · Phase 2
Open-label Extension Study of Brazikumab in Ulcerative Colitis
A Phase 2 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT04277546 is a Phase 2 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 57 participants.
The verdict
NCT04277546, a Phase 2 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
The purpose of this OLE Study D5272C00002 (Legacy #3151-202-008) is to permit participants who previously enrolled in the double-blind Study D5272C00001 (Legacy #3151-201-008) to receive brazikumab, allowing for long-term observation of safety and efficacy in these participants treated with brazikumab. There are no formal hypotheses to be tested. Safety and efficacy data obtained in this study will be included in regulatory product submissions as appropriate.
Interventions
- DRUG Brazikumab Induction Dose
- DRUG Brazikumab Maintenance Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2020-03-03 |
| Est. Completion | 2023-10-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04277546
The ClinicalTrials.gov registry entry for NCT04277546 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Brazikumab Induction Dose is the first listed.
NCT04277546 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04277546 about?
NCT04277546 is a clinical study titled "Open-label Extension Study of Brazikumab in Ulcerative Colitis". The purpose of this OLE Study D5272C00002 (Legacy #3151-202-008) is to permit participants who previously enrolled in the double-blind Study D5272C00001 (Legacy #3151-201-008) to receive brazikumab, allowing for long-term observation of safety and efficacy in these participants treated with brazikum...
What is the current status of trial NCT04277546?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2020-03-03. Estimated completion is 2023-10-10.
What interventions are being tested in trial NCT04277546?
The interventions under investigation include: Brazikumab Induction Dose (DRUG), Brazikumab Maintenance Dose (DRUG).
Who is sponsoring clinical trial NCT04277546?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.